<DOC>
	<DOCNO>NCT00734734</DOCNO>
	<brief_summary>Trial annual approval interpandemic influenza vaccine</brief_summary>
	<brief_title>Safety Immunogenicity Surface Antigen , Inactivated , Adjuvanted With MF59C.1 Influenza Vaccine , Formulation 2008-2009</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Key 65 year age old Mentally competent Willing able give write informed consent prior study entry Able comply study requirement In general good health Key Any serious chronic acute disease History anaphylactic reaction and/or serious allergic reaction follow vaccination , proven hypersensitivity component study vaccine ( e.g . ovalbumin , chicken protein , chicken feather , influenza viral protein , kanamycin neomycin sulphate ) ; Known suspect ( high risk develop ) impairment/alteration immune function ( exclude normally associate advanced age ) Receipt parenteral immunoglobulin preparation , blood product and/or plasma derivates within past 3 month full length study ; suspect know HIV infection HIVrelated disease A bleeding diathesis condition associate prolonged bleeding time investigator 's opinion would interfere safety subject Within past 12 month , receive one injection influenza vaccine Within past 6 month , participant laboratory confirm influenza disease ; receive influenza vaccine Within past 4 week participant receive another vaccine ; investigational agent An acute exacerbation COPD ( chronic obstructive pulmonary disease ) within past 14 day</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Prophylaxis Influenza</keyword>
	<keyword>Influenza Vaccines</keyword>
	<keyword>MF59C.1</keyword>
</DOC>